Abbreviations: HCT = hematopoietic cell transplant; IQR = interquartile range. Numbers of patients in each category (out of a total cohort of 163), with percentages of total in parentheses.
Although hematopoietic cell transplantation (HCT) is an increasingly powerful tool for inducing remission or cure in a variety of hematologic malignancies, many patients will ultimately succumb to their disease or to complications of HCT. End-of-life care in patients with hematologic malignancies can be uniquely challenging because of the absence of clear transition points between curative and palliative phases of care, the severity of treatmentrelated complications, and the potential in many cases for significantly life-prolonging transfusion support, all of which hamper accurate prognosis and management. [1] [2] [3] [4] Moreover, misconceptions among both patients and clinicians about the role of palliative care and its relationship to 'aggressive treatment' contribute to delayed goals of care conversations (GOCs), decreased or delayed utilization of specialty palliative care and hospice services, high rates of aggressive interventions at the end of life, and a high proportion of in-hospital deaths. 5, 6 In patients with solid tumors, palliative care consultations soon after diagnosis have been associated with better symptom control, patient satisfaction, hospice utilization and life expectancy. 7, 8 But, relative to patients with solid tumor malignancies, patients with hematologic malignancies are less likely to receive specialty palliative care referrals or to die in a hospice. 6 Of all patients with hematologic malignancies, those who undergo HCT represent a unique subset of patients who are potentially more likely to receive aggressive care at the end of life. 9 There has yet to be a large, comprehensive study of advance care planning and specialty palliative care utilization specifically in adults with hematologic malignancies who undergo HCT.
We conducted a single-center, retrospective cohort study of 163 patients treated with HCT for a hematologic malignancy who died between January 2012 and December 2015 at the University of California San Francisco (UCSF) Medical Center, with the goal of both describing utilization and identifying predictors of advance care planning and end-of-life care in this population. Of the 215 patients initially identified through our institutional transplant database, 20 were excluded because they died over a year after their last visit and were considered lost to follow-up, and an additional 32 were excluded because the circumstances of their deaths were unknown. This left 163 total patients available for analysis, or 76% of eligible patients. Demographic information (age, sex, race and preferred language), diagnostic data (primary diagnosis and date of diagnosis) and treatment history (pre-HCT conditioning regimen, HCT type, graft source and dates of treatment) were compiled from our institutional database and independently verified using the UCSF electronic medical record system. Information pertaining to end-of-life care was subsequently abstracted, including number and duration of any hospitalizations that occurred within 1 year of death, location of death, admitting diagnosis and length of final hospital stay if the patient died in a hospital, whether the patient was receiving chemotherapy at the time of death, documentation of specialty palliative care involvement, code status at the time of and prior to death, documentation of outpatient GOCs, and presence of an Advance Directive (AD) or Physician's Orders for Life-Sustaining Treatment (POLST).
Patient, disease and transplant characteristics are shown in Table 1 . The study sample was 53% male, 67% white, and 90% of patients preferred to communicate in English. The most common diagnoses were multiple myeloma (34%) and acute myeloid leukemia (27%). Fifty-one percent of patients received allografts, while 49% received autografts. In a sensitivity analysis, patients who were excluded did not differ significantly from patients included in the analysis, with the exception that more patients in the excluded group underwent autologous HCT. Only 26% of patients had documentation of an outpatient GOC (Figure 1) . Similarly, only 33% of patients completed ADs and only 11% completed POLSTs. On the contrary, the majority of patients (53%) received a specialty palliative care consultation. However, the median number of days between first palliative care consultation and death was only 15 days, and only 21% of patients received a palliative care consult more than 30 days prior to their death. Inpatient hematology/oncology providers made 66% of specialty palliative care referrals, while only 14% of referrals came from the outpatient setting.
In univariate analysis, patients who were hospitalized for 460 days in their last year of life were more likely to receive a palliative care consultation (P o0.0001), as were those who survived over a year after transplant (P = 0.045). Demographics also had a significant impact on advance care planning, with non-English speakers being less likely to have a documented outpatient goals of care discussion (P = 0.043).
Forty-one percent of patients received chemotherapy within 30 days of death. The majority of patients (51%) died in a hospital, with 26% dying in an ICU and 25% dying in an inpatient acute care unit. Twenty-eight percent of patients died in home hospice and 12% died in inpatient hospice. While 80% of patients had a code status of Do Not Resuscitate/Do Not Intubate (DNR/DNI) at the time of death, only 17% of patients were DNR/DNI more than 30 days before death.
In univariate analysis, demographic factors had a significant impact on the location of a patient's death. Non-English speakers, as well as patients of non-white race, were found to be more likely to die either in an ICU or in a non-ICU acute care setting (P = 0.016 and P = 0.027, respectively). There was also a trend toward patients under the age of 40 being more likely to die in a hospital (P = 0.086). In multivariate analysis, patients who received specialty palliative care consultations at any time prior to death were significantly less likely to die in the ICU as compared to either a non-ICU acute care setting (hazard ratio 0.59, confidence interval 0.36-0.98; P = 0.039) or a hospice setting (hazard ratio 0.56, confidence interval 0.35-0.91; P = 0.019). Eighty-four percent of patients who died while on hospice had received a palliative care consultation versus only 31% of those who died in the ICU (Po0.0001).
Patients who had documentation of any component of an advance care plan-defined as having a documented outpatient GOC, an AD, a POLST, and/or a code status of DNR/DNI more than 30 days prior to death-were more likely to die in a hospice than either in an ICU (P = 0.001) or in a non-ICU acute care setting (P = 0.004). Sixty percent of patients who died in hospice had some component of a documented advance care plan versus only 29 and 33% of those who died in an ICU or a non-ICU acute care setting, respectively.
In this study, we show that despite high rates of disease-and treatment-related morbidity and mortality associated with HCT, patients who underwent HCT had low rates of early specialty palliative care referral, were unlikely to discuss end-of-life preferences early in their disease course, were likely to receive aggressive interventions immediately prior to death, and commonly died in an acute care setting. Both advance care planning and specialty palliative care consultation were associated with increased hospice utilization and decreased in-hospital deaths.
Relative to the studies looking at all patients with hematologic malignancies-not just those who undergo HCT-specialty palliative care utilization in our cohort was higher, a finding likely explained by higher rates of inpatient deaths and the associated increased availability of specialty palliative care services, particularly in the window immediately prior to death. The observed impact of advance care planning and palliative care utilization on the location of a patient's death is also consistent with published literature for non-HCT recipients. Advance care planning alone has been shown to significantly reduce the number of days that patients-both with and without cancer-spend in a hospital in the last year of life. 10 Given the existing data related to the benefit of advance care planning and early palliative care utilization in solid tumor malignancies, it is somewhat surprising that over 40% of all patients in this study lacked any component of an advance care plan, although it is possible that advance care planning was discussed, but not documented. This is also potentially explained by the unpredictable nature of the post-HCT disease course, the fact that most patients undergo HCT with curative intent, and that there have been no HCT-specific data supporting advance care planning to this point.
This study has several limitations. As with any retrospective cohort study, we show associations but are unable to prove causation. Additionally, as the data all come from a single tertiary care center, it is possible that these findings are not generalizable to other settings, although our center is likely similar in most regards to other major referral centers where HCT is routinely performed. Finally, the sample size-although the largest of its kind to date-may have limited statistical conclusions.
In summary, in this study both advance care planning and specialty palliative care consultations were associated with a reduced likelihood of dying in an ICU or acute care setting, and an increased likelihood of dying in hospice. As per several recent publications, strategies to promote advance care planning and early, integrated palliative care utilization for patients who undergo HCT warrant ongoing prospective evaluation. 
